Real‐world evidence of F‐fluciclovine Positron emission tomography/computed tomography performance for recurrent prostate cancer in the Veterans Affairs Health System

Published on 07/25/2024

Reading time: 4 min.

Nadine A. Friedrich MD ¹, Lin Gu MS ², Justin Waller MS ², Amanda M. De Hoedt MS ², Zachary Klaassen MD, MSc ^2,3,4, Stephen J. Freedland MD ^1,2

¹ Division of Urology, Department of Surgery Cedars‐Sinai Medical Center Los Angeles California USA
² Durham Veterans Affairs Health Care System Durham North Carolina USA
³ Division of Urology, Department of Surgery, Medical College of Georgia Augusta University Augusta Georgia USA
⁴ Georgia Cancer Center Augusta Georgia USA

Abstract

Background There are no population‐level studies assessing ¹⁸F‐fluciclovine (fluciclovine) utilization of Positron emission tomography/computed tomography (PET/CT) for biochemically recurrent prostate cancer (PC). We assessed fluciclovine PET/CT in the Veterans Affairs Health Care System.
Methods Of 1153 men with claims suggesting receipt of fluciclovine PET/CT, we randomly reviewed charts of 300 who indeed underwent fluciclovine...

To continue reading this article in Full-Text...

Access request*

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

The Prostate

Peer-Reviewed Journals A-Z

Search | Advanced search

Advertisement..

Get the latest news in Oncology

Receive our newsletter to stay up to date with the latest news in Oncology

Access request

From peer-reviewed journals in Oncology